Re: RE: removed from group

[Guest guest]

I just unsubscribed from the non-rhythmic list, before he unsubscribes me because once he reads the posts I wrote him he will.

Thanks for the headsup . I trust my doctor will help me look out for these things too, but it always is best to have all the information we can get before we go see our doctor, to help them to their best job. They learn from US!

RE: removed from group

Dear Neil,

I inadvertently posted to the wrong list, but I'm happy could read my warning about checking for uterine hyperplasia at one year. If the WP is tested, tried and true, no one should be sensitive about a warning of possible hyperplasia. There are women on the other list who got hyperplasia on WP. One woman did get endometrial cancer on P cream. Below is the study I referred to. However, do not reinstate me. I don't want to be on your list.

Here's another good one: http://www.mja.com.au/public/issues/182_05_070305/wre10534_fm.html

Val

BJOG. 2005 Oct;112(10):1402-6.

Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime.

Vashisht A, Wadsworth F,

Carey A, Carey B, Studd J.

Chelsea and Westminster Hospital, London, UK.

OBJECTIVE: Many women are seeking alternatives to conventional forms of hormone replacement. This study evaluates the endometrial effects of natural progesterone cream used in conjunction with transdermal oestradiol. DESIGN: Open plan study conducted over 48 weeks. SETTING: Tertiary referral London teaching hospital. POPULATION: Women at least two years postmenopausal. METHODS: Women were recruited nationally. They applied 40 mg transdermal natural progesterone cream and 1 mg transdermal oestradiol daily. MAIN OUTCOME MEASURES: Endometrial histology, assessed by pipelle endometrial biopsy, ultrasound assessment of endometrial thickness and bleeding diaries. RESULTS: Fifty-four women were recruited of which 41 completed the study. Mean age was

57.4 years. Thirty-two percent of women had evidence of inadequate endometrial opposition (proliferative or hyperplastic) at the end of 48 weeks. At baseline, women had a mean endometrial thickness of 3.3 mm, which had significantly thickened to a mean of 5.3 mm by 24 weeks (P < 0.001). By 48 weeks, there was significantly greater increase in endometrial thickness from baseline in those women who displayed inadequate endometrial opposition, compared with those women who had adequate endometrial opposition (P= 0.004). At 24 weeks, 48% of women had remained entirely amenorrhoeic. By the end of the study, 35% of women had been entirely amenorrhoeic and 50% had had either no bleeding or spotting alone. The number of bleeding episodes did not reduce with time. CONCLUSIONS: The dose of natural progesterone cream in this study was insufficient to fully attenuate the mitogenic effect of oestrogen on the endometrium. We would not recommend this combination of hormones to be used by postmenopausal women.

Climacteric. 2000 Sep;3(3):155-60.

Comment in:

· Climacteric. 2000 Sep;3(3):153-4.

Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women.Wren BG, McFarland K, L, O'Shea P, Sufi S, Gross B, Eden JA.Sydney Menopause Centre, Royal Hospital for Women, Barker Street, Randwick, New South Wales 2031, Australia.BACKGROUND: Transdermal progesterone is being used in some countries as a purported treatment for menopausal symptoms, either alone or prescribed in conjunction with estrogen, but little information exists regarding the biological activity and effectiveness of this method of delivery of progesterone in protecting the endometrium from excess proliferation. This study was designed to evaluate the use of sequential transdermal progesterone. End-points evaluated included endometrial cellular response and bleeding pattern as well as plasma hormone levels and salivary progesterone estimations. METHOD: Twenty-seven postmenopausal women were treated with continuous transdermal estrogen (28-day cycle) and a cream containing 16, 32 or 64 mg of progesterone in each 4-cm extrusion from a tube of Pro-Feme administered daily in a sequential (days 15-28 of cycle) regimen. Blood and endometrial samples were analyzed for progesterone response prior to therapy, after the first 14 days of unopposed transdermal estrogen and following 14 days of transdermal progesterone. Saliva samples were taken during the last 14 days of the 84-day study, when the final progesterone cream therapy was being applied. RESULTS: Hormone assay indicated that physiological levels of estradiol were achieved, but progesterone levels were insufficient to induce any detectable change in the endometrium. Only one patient experienced bleeding during the study period. Levels of salivary progesterone were so variable as to be considered completely unreliable in determining the potential influence on biological activity. INTERPRETATION: Pro-Feme transdermal progesterone administered in a 16-, 32- or 64-mg daily dose for 14 days in a sequential regimen does not appear to be effective in inducing a secretory change in a proliferative endometrium. Salivary progesterone levels were not of value in managing the therapy of postmenopausal women.Publication Types:

Clinical Trial

Randomized Controlled Trial

PMID: 11910616 [PubMed - indexed for MEDLINE]

-----Original Message-----From: Neil Raden Sent: Wednesday, April 05, 2006 8:53 PMTo: val@...Subject: removed from group

I’ve removed you from the NotRhythmicLiving group for posting a message that claims research that you have not shared. If you can satisfy that you have this information, I will reinstate you and your message. No one I’ve checked with ever heard of this study and, frankly, it is impossible because no one actually has a list of all the people on the WP, many people think they are on the WP but are not.

-NR

Neil Raden nraden@...

Hired Brains, Inc.

Santa Barbara, CA

www.hiredbrains.com/knowout.html

t

[Guest guest]

Is this found in a routine pap smear gyn. exam, the kind I have every year? Or does it require more specialized testing?

RE: removed from group

Dear Neil,

I inadvertently posted to the wrong list, but I'm happy could read my warning about checking for uterine hyperplasia at one year. If the WP is tested, tried and true, no one should be sensitive about a warning of possible hyperplasia. There are women on the other list who got hyperplasia on WP. One woman did get endometrial cancer on P cream. Below is the study I referred to. However, do not reinstate me. I don't want to be on your list.

Here's another good one: http://www.mja.com.au/public/issues/182_05_070305/wre10534_fm.html

Val

BJOG. 2005 Oct;112(10):1402-6.

Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime.

Vashisht A, Wadsworth F,

Carey A, Carey B, Studd J.

Chelsea and Westminster Hospital, London, UK.

OBJECTIVE: Many women are seeking alternatives to conventional forms of hormone replacement. This study evaluates the endometrial effects of natural progesterone cream used in conjunction with transdermal oestradiol. DESIGN: Open plan study conducted over 48 weeks. SETTING: Tertiary referral London teaching hospital. POPULATION: Women at least two years postmenopausal. METHODS: Women were recruited nationally. They applied 40 mg transdermal natural progesterone cream and 1 mg transdermal oestradiol daily. MAIN OUTCOME MEASURES: Endometrial histology, assessed by pipelle endometrial biopsy, ultrasound assessment of endometrial thickness and bleeding diaries. RESULTS: Fifty-four women were recruited of which 41 completed the study. Mean age was

57.4 years. Thirty-two percent of women had evidence of inadequate endometrial opposition (proliferative or hyperplastic) at the end of 48 weeks. At baseline, women had a mean endometrial thickness of 3.3 mm, which had significantly thickened to a mean of 5.3 mm by 24 weeks (P < 0.001). By 48 weeks, there was significantly greater increase in endometrial thickness from baseline in those women who displayed inadequate endometrial opposition, compared with those women who had adequate endometrial opposition (P= 0.004). At 24 weeks, 48% of women had remained entirely amenorrhoeic. By the end of the study, 35% of women had been entirely amenorrhoeic and 50% had had either no bleeding or spotting alone. The number of bleeding episodes did not reduce with time. CONCLUSIONS: The dose of natural progesterone cream in this study was insufficient to fully attenuate the mitogenic effect of oestrogen on the endometrium. We would not recommend this combination of hormones to be used by postmenopausal women.

Climacteric. 2000 Sep;3(3):155-60.

Comment in:

· Climacteric. 2000 Sep;3(3):153-4.

Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women.Wren BG, McFarland K, L, O'Shea P, Sufi S, Gross B, Eden JA.Sydney Menopause Centre, Royal Hospital for Women, Barker Street, Randwick, New South Wales 2031, Australia.BACKGROUND: Transdermal progesterone is being used in some countries as a purported treatment for menopausal symptoms, either alone or prescribed in conjunction with estrogen, but little information exists regarding the biological activity and effectiveness of this method of delivery of progesterone in protecting the endometrium from excess proliferation. This study was designed to evaluate the use of sequential transdermal progesterone. End-points evaluated included endometrial cellular response and bleeding pattern as well as plasma hormone levels and salivary progesterone estimations. METHOD: Twenty-seven postmenopausal women were treated with continuous transdermal estrogen (28-day cycle) and a cream containing 16, 32 or 64 mg of progesterone in each 4-cm extrusion from a tube of Pro-Feme administered daily in a sequential (days 15-28 of cycle) regimen. Blood and endometrial samples were analyzed for progesterone response prior to therapy, after the first 14 days of unopposed transdermal estrogen and following 14 days of transdermal progesterone. Saliva samples were taken during the last 14 days of the 84-day study, when the final progesterone cream therapy was being applied. RESULTS: Hormone assay indicated that physiological levels of estradiol were achieved, but progesterone levels were insufficient to induce any detectable change in the endometrium. Only one patient experienced bleeding during the study period. Levels of salivary progesterone were so variable as to be considered completely unreliable in determining the potential influence on biological activity. INTERPRETATION: Pro-Feme transdermal progesterone administered in a 16-, 32- or 64-mg daily dose for 14 days in a sequential regimen does not appear to be effective in inducing a secretory change in a proliferative endometrium. Salivary progesterone levels were not of value in managing the therapy of postmenopausal women.Publication Types:

Clinical Trial

Randomized Controlled Trial

PMID: 11910616 [PubMed - indexed for MEDLINE]

-----Original Message-----From: Neil Raden Sent: Wednesday, April 05, 2006 8:53 PMTo: val@...Subject: removed from group

I’ve removed you from the NotRhythmicLiving group for posting a message that claims research that you have not shared. If you can satisfy that you have this information, I will reinstate you and your message. No one I’ve checked with ever heard of this study and, frankly, it is impossible because no one actually has a list of all the people on the WP, many people think they are on the WP but are not.

-NR

Neil Raden nraden@...

Hired Brains, Inc.

Santa Barbara, CA

www.hiredbrains.com/knowout.html

t